Operator
Good morning, ladies and gentlemen, and thank you for joining us today for MindWalk’s Second Quarter Fiscal 2026 Earnings Call. We appreciate your time and interest in MindWalk, formerly ImmunoPrecise Antibodies.
Today’s call will be led by our CEO, Dr. Jennifer Bath and our CFO, Scott Areglado. They will provide a review of our financial performance, strategic initiatives and key operational highlights for the second quarter. A copy of today’s presentation, along with our final financial statements and MD&A is available on our website.
Before we begin, I’d like to remind everyone that today’s discussion will include forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could results, include among others, global political and economic conditions, changes in the market dynamics, competitive developments and other business risks. Unless otherwise noted, all financial figures discussed today are in Canadian dollars. These statements are made as of today, and MindWalk undertakes no obligation to update them, except as required by law.
For a more detailed discussion of risks and uncertainties, please refer to our filings with the SEC and Canadian securities regulators, including our most recent Form 20-F and other periodic reports.
I would now like to turn the call over to MindWalk’s President and CEO, Dr. Jennifer Bath.
Jennifer Bath
CEO, President & Non-Independent Director
Thank you, Regina. Good morning everyone. Before i discuss our quarter, marked by strong financial performance, I want to frame
